Related Experiment Videos
Characterization of the inhibitory effects of transforming growth factor-beta on a human colon carcinoma cell line
Abstract:
The effects of transforming growth factor-beta (TGF beta) on a human colon carcinoma cell line (MOSER) were investigated. TGF beta, at low concentrations (between 0.1 and 1.0 ng/ml), inhibited the proliferation of MOSER cells both in monolayer culture and soft agarose, in a dose-dependent manner. MOSER cells adapted to growth in chemically defined serum-free medium were more sensitive to the inhibitory effects of TGF beta than cells maintained in serum-supplemented medium. Morphological changes in MOSER cells, observed with TGF beta, were similar to those seen with the chemical differentiation agent N,N-dimethylformamide. Also in similarity to the effects of N,N-dimethylformamide, TGF beta induced a time- and concentration-dependent increase in soluble extracellular fibronectin. Binding studies with [125I]TGF beta revealed a relatively low number of binding sites on MOSER cells (13%) compared with mouse embryo fibroblastic (AKR-2B) cells. Thus far, other colon carcinoma cell lines, some displaying TGF beta receptors, have been reported to be unresponsive to TGF beta. This study is therefore the first to demonstrate a TGF beta-responsive colon carcinoma cell line.
Insights
This study shows that transforming growth factor-beta (TGF-β) inhibits human colon cancer cell growth. MOSER cells, a colon carcinoma line, are responsive to TGF-β, unlike other lines.
Area of Science:
- Oncology
- Cell Biology
- Molecular Biology
Background:
- Transforming growth factor-beta (TGF-β) plays a role in cell growth and differentiation.
- Many colon carcinoma cell lines are unresponsive to TGF-β.
- Understanding TGF-β's effects on colon cancer is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the effects of TGF-β on the human colon carcinoma cell line MOSER.
- To determine if MOSER cells are responsive to TGF-β.
- To characterize the cellular and molecular changes induced by TGF-β in MOSER cells.
Main Methods:
- Cell culture of MOSER cells in monolayer and soft agarose.
- Treatment with varying concentrations of TGF-β.
- Assessment of cell proliferation, morphology, and extracellular fibronectin expression.
- Binding studies using radiolabeled TGF-β.
Main Results:
- TGF-β inhibited MOSER cell proliferation in a dose-dependent manner.
- Serum-free conditions enhanced MOSER cell sensitivity to TGF-β.
- TGF-β induced morphological changes and increased fibronectin, similar to N,N-dimethylformamide.
- MOSER cells exhibited a low number of TGF-β binding sites.
Conclusions:
- The MOSER cell line is the first reported colon carcinoma cell line responsive to TGF-β.
- TGF-β exhibits anti-proliferative effects on this specific colon cancer cell line.
- These findings suggest potential therapeutic avenues targeting TGF-β signaling in certain colon cancers.